BFLY vs QSI

Key Takeaways

• Butterfly Network (BFLY) has demonstrated accelerating commercial momentum, reporting record quarterly revenue of $31.5 million in Q4 2025 and guiding for 20%–24% revenue growth in 2026.
• Quantum-Si (QSI) remains a pre-revenue-stage growth story in practical terms, with full-year 2025 revenue of just $2.4 million and 2026 guidance of approximately $1 million as the company treats the year as a transition period ahead of its Proteus platform launch.
• BFLY's market capitalization of approximately $1.86 billion vastly exceeds QSI's roughly $153 million, reflecting a substantial gap in scale, revenue generation, and market validation.
• Both companies are developing next-generation platforms — BFLY's Apollo AI chip and QSI's Proteus — but BFLY already has a commercialized product ecosystem generating meaningful revenue, while QSI is still building toward its pivotal launch.
• From a trend and stability perspective, BFLY has posted a roughly 288% one-year gain with improving fundamentals, whereas QSI has declined approximately 58% over the past year amid a pre-commercial transition phase.
• Both stocks carry elevated risk profiles typical of emerging technology companies, but BFLY's established revenue base and path toward EBITDA (earnings before interest, taxes, depreciation, and amortization) breakeven offer comparatively greater visibility.

Introduction

Comparing BFLY and QSI offers investors a window into two distinct approaches to life sciences innovation. Butterfly Network is a digital health company that has commercialized handheld, semiconductor-based ultrasound technology and is now layering AI-powered software and enterprise workflow solutions on top of its hardware platform. Quantum-Si is a proteomics company developing single-molecule protein sequencing technology, currently navigating the delicate transition from early commercialization of its first-generation Platinum Pro system toward the anticipated late-2026 launch of its flagship Proteus platform. While both companies operate at the intersection of technology and biology, they sit at very different points on the commercialization curve. This comparison is particularly relevant for growth-oriented investors evaluating risk-reward profiles in the healthcare technology sector.

BFLY Overview and Recent Performance

Butterfly Network (BFLY) has undergone a notable transformation in recent quarters. The company, known for its proprietary Ultrasound-on-Chip™ semiconductor technology and handheld whole-body ultrasound probes, reported record quarterly revenue of $31.5 million in Q4 2025 — a 41% year-over-year increase. For the full year 2025, revenue landed within the guided range of $91 million to $95 million, and management has issued 2026 guidance of $117 million to $121 million, implying approximately 20%–24% growth. Importantly, BFLY achieved its first quarter of positive operating cash flow in Q4 2025, signaling that its financial discipline is beginning to pay off.

Several catalysts have shaped sentiment. The co-development partnership with Midjourney, which contributed $6.8 million in Q4 revenue and could deliver up to $74 million over five years, demonstrates the licensing potential of the company's ultrasound-on-chip platform beyond traditional medical imaging. The launch of Compass™ AI, an enterprise software platform for point-of-care ultrasound (POCUS) workflow, has expanded the addressable market within hospital systems. Additionally, the company advanced its P5.1 chip into production and initiated development of the Apollo AI chip, which is expected to deliver significantly greater processing power for next-generation applications. The stock has responded dramatically, climbing from a 52-week low of $1.32 to recent trading levels around $7.10, reflecting a market capitalization near $1.86 billion. Analysts have maintained a consensus "Strong Buy" rating with a price target near $7.06.

QSI Overview and Recent Performance

Quantum-Si (QSI) is approaching a defining moment in its corporate trajectory. The company's core technology platform enables single-molecule protein sequencing — an emerging field within proteomics that aims to do for proteins what next-generation sequencing did for DNA. However, QSI remains in the earliest stages of commercialization. Full-year 2025 revenue totaled just $2.4 million, and the company has guided for 2026 revenue of approximately $1 million, explicitly describing the year as a "transition year." The deliberate revenue decline reflects strategic choices: embedding upgrade credits into current Platinum Pro units and seeing customers delay purchasing decisions as they await the Proteus platform, now expected to launch by the end of 2026.

On the development front, QSI has achieved meaningful milestones. The company demonstrated successful protein sequencing on a prototype Proteus system in late 2025 and announced a list price of $425,000 for the platform. Management has emphasized that the Proteus program remains on track for a year-end 2026 launch. The company completed a $50 million registered direct offering in mid-2025, and cash and equivalents stood at $215.8 million as of December 31, 2025 — providing a runway into the second quarter of 2028. Despite these positives, the stock has faced sustained pressure. Shares have declined approximately 58% over the past year, recently trading around $0.70, giving the company a market capitalization of roughly $153 million. The 52-week range spans from $0.69 to $3.10, and a beta of 3.20 indicates significantly higher volatility than the broader market. While analysts maintain a consensus "Buy" rating, with an average price target of $2.50, the near-term revenue picture remains subdued as the company invests heavily in Proteus readiness.

Trending AI Robots

In rapidly evolving markets like healthcare technology, many traders and investors are turning to AI-driven tools to help navigate uncertainty and identify opportunities. Tickeron's Trending AI Robots page features a curated selection of the platform's best-performing AI trading bots, drawn from a broader library of hundreds of bots that trade thousands of different tickers across multiple strategies, timeframes, and sectors. Only those bots demonstrating the strongest alignment with current market conditions earn a place in this section. The bots employ diverse approaches — from swing trading and trend following to volatility-based strategies — and their performance statistics vary widely, with some showcasing annualized returns above 70%, win rates exceeding 75%, and profit factors well above 2.0. Each bot operates with a distinct set of parameters, trading styles, and tracked ticker universes, allowing users to explore strategies that match their individual preferences. For those interested in augmenting their market analysis with AI-driven signals, the Trending AI Robots page provides a useful starting point for discovery.

Head-to-Head Comparison

The contrast between BFLY and QSI is most pronounced when examining the commercialization gap. BFLY generated over $100 million in trailing twelve-month revenue with expanding gross margins (adjusted gross margin of 67.5% in Q4 2025) and a clear path toward EBITDA breakeven. QSI, by comparison, generated under $2 million in trailing revenue with management guiding even lower in 2026 as it prioritizes platform readiness over near-term sales. This is not inherently negative — pre-revenue biotech and life sciences companies often trade on future potential — but it does create a fundamentally different risk profile.

Both companies are pursuing platform strategies with recurring revenue ambitions. BFLY's enterprise software (Compass AI) and embedded licensing (Midjourney partnership) add layers of high-margin recurring and milestone-based revenue on top of probe sales. QSI's business model envisions a razor-and-blade dynamic, with instrument placements driving recurring consumables revenue, but the installed base remains small and the pivotal Proteus platform is not yet commercialized.

Risk factors also diverge. BFLY faces execution risk in scaling enterprise sales and maintaining growth momentum, but is already demonstrating commercial traction. QSI faces the binary risk of a major platform launch — if Proteus encounters delays or underperforms expectations, the stock could face significant additional pressure. On the other hand, a successful Proteus launch could dramatically reshape QSI's revenue trajectory. Sector exposure differs as well: BFLY operates in the established medical device and imaging market, competing on portability, AI integration, and cost, while QSI targets the earlier-stage proteomics market, which carries higher potential upside but also greater adoption uncertainty.

Tickeron AI Verdict

Based on observable factors — including trend consistency, revenue trajectory, cash flow generation, and relative market positioning — Tickeron's AI-driven analysis would likely favor BFLY over QSI in the current environment. BFLY's combination of accelerating revenue growth, improving margins, positive operating cash flow, and a diversified strategy spanning medical devices, enterprise software, and semiconductor licensing presents a more balanced risk-reward profile with multiple catalysts already materializing. QSI's value proposition remains almost entirely tied to a single future event — the Proteus launch — which, while potentially transformative, introduces a wide range of outcomes. The probability-weighted assessment, at present, tilts toward the company demonstrating commercial execution and momentum today rather than the one building toward a pivotal milestone tomorrow. That said, traders with higher risk tolerance and longer time horizons may find QSI's asymmetry worth monitoring closely, given that a successful Proteus debut could alter the company's trajectory substantially.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations